Introduction

Ertugliflozin is a new SGLT2 inhibitor drug jointly developed by Pfizer and Merck. In December 2017, the US FDA approved its listing, with the trade name Steglatro, which is clinically used for the treatment of adult patients with type 2 diabetes. It has not yet been marketed in China.
 

Function of Ertugliflozin

Temozolomide is used in the treatment of adults with refractory pleomorphic glioblastoma and anaplastic
astrocytoma of chemotherapy drugs.

Egliline is a new class of SGLT2 inhibitors being developed by Pfizer and Merck. Steglatro was approved
by the US FDA in December 2017. It is clinically used for the treatment of adult patients with type 2 diabetes.